Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $57.29.

Several research firms have issued reports on IRON. BMO Capital Markets lowered their price objective on shares of Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday, April 2nd. Stifel Nicolaus boosted their price objective on shares of Disc Medicine from $71.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Morgan Stanley lowered their price objective on shares of Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Disc Medicine in a research report on Monday, April 1st. Finally, Raymond James reissued an “outperform” rating and issued a $40.00 price objective (down from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st.

Disc Medicine Trading Up 2.7 %

IRON stock opened at $29.79 on Monday. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The company has a 50-day moving average price of $47.32 and a 200 day moving average price of $54.08. The stock has a market cap of $719.13 million, a PE ratio of -8.54 and a beta of 0.44.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). Sell-side analysts forecast that Disc Medicine will post -4.44 EPS for the current year.

Insider Activity at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 2,560 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.71% of the stock is owned by insiders.

Institutional Trading of Disc Medicine

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new position in shares of Disc Medicine during the third quarter worth $28,000. AJOVista LLC purchased a new position in shares of Disc Medicine during the 4th quarter valued at about $63,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Disc Medicine in the 4th quarter valued at about $161,000. Bleakley Financial Group LLC acquired a new position in shares of Disc Medicine in the 4th quarter valued at about $215,000. Finally, Simplicity Solutions LLC purchased a new stake in shares of Disc Medicine in the fourth quarter worth about $215,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.